{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:35:09Z","timestamp":1761060909524,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jemermed.2019.09.038","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T07:59:57Z","timestamp":1572076797000},"page":"e167-e173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Idarucizumab for Reversal of Dabigatran in Early\/Emergency Surgeries: A Case Series"],"prefix":"10.1016","volume":"57","author":[{"given":"W. Frank","family":"Peacock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Grotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2019.09.038_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/DDDT.S45644","article-title":"New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness","volume":"8","author":"Mani","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jemermed.2019.09.038_bib2","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1161\/CIRCULATIONAHA.114.010426","article-title":"Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose?","volume":"130","author":"Wadhera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2019.09.038_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/CIRCULATIONAHA.116.022307","article-title":"Urgent need to measure effects of direct oral anticoagulants","volume":"134","author":"Weitz","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2019.09.038_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1183\/09031936.00059814","article-title":"Ageing and the epidemiology of multimorbidity","volume":"44","author":"Divo","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jemermed.2019.09.038_bib5","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2019.09.038_bib6","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab: the antidote for reversal of dabigatran","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2019.09.038_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2019.09.038_bib8","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/STROKEAHA.116.013550","article-title":"Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab","volume":"47","author":"Berrouschot","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jemermed.2019.09.038_bib9","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.12.037","article-title":"Acute stroke despite dabigatran anticoagulation treated with idarucizumab and intravenous tissue plasminogen activator","volume":"26","author":"Bissig","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jemermed.2019.09.038_bib10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11239-017-1485-1","article-title":"Intravenous thrombolysis for stroke after dabigatran reversal with idarucizumab: an update","volume":"43","author":"Cappellari","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jemermed.2019.09.038_bib11","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/MBC.0000000000000634","article-title":"Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report","volume":"28","author":"Facchinetti","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jemermed.2019.09.038_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13256-016-1050-0","article-title":"Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report","volume":"10","author":"Gawehn","year":"2016","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.jemermed.2019.09.038_bib13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000447531","article-title":"Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a case report","volume":"8","author":"Kafke","year":"2016","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.jemermed.2019.09.038_bib14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/acn3.346","article-title":"Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report","volume":"3","author":"Mutzenbach","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jemermed.2019.09.038_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00415-017-8410-6","article-title":"Adverse clinical outcomes after dabigatran reversal with idarucizumab to\u00a0facilitate acute stroke thrombolysis","volume":"264","author":"Ng","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.jemermed.2019.09.038_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40263-017-0460-x","article-title":"Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving alteplase: a systematic review of the available evidence","volume":"31","author":"Pikija","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jemermed.2019.09.038_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11910-017-0774-6","article-title":"Non-vitamin K oral anticoagulants (NOACs) and their reversal","volume":"17","author":"Reddy","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.jemermed.2019.09.038_bib18","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.05.006","article-title":"Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab-a case report","volume":"25","author":"Sch\u00e4fer","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jemermed.2019.09.038_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jns.2016.09.010","article-title":"Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke","volume":"370","author":"Schulz","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jemermed.2019.09.038_bib20","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.03.039","article-title":"Systemic thrombolysis in acute ischemic stroke after dabigatran etexilate reversal with idarucizumab\u2014a case report","volume":"26","author":"Tireli","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jemermed.2019.09.038_bib21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13760-017-0751-5","article-title":"Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer","volume":"117","author":"Turine","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.jemermed.2019.09.038_bib22","first-page":"1","article-title":"Idarucizumab in three patients needing urgent surgical intervention and one case of intravenous thrombolysis in ischaemic stroke","volume":"4","author":"von Wowern","year":"2017","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.jemermed.2019.09.038_bib23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11239-017-1476-2","article-title":"Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases","volume":"43","author":"Vosko","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jemermed.2019.09.038_bib24","doi-asserted-by":"crossref","first-page":"662.e3","DOI":"10.1016\/j.ajem.2016.10.068","article-title":"Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab","volume":"35","author":"Braemswig","year":"2017","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jemermed.2019.09.038_bib25","first-page":"579","article-title":"Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome","volume":"126","author":"Mazur","year":"2016","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.jemermed.2019.09.038_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/bcpt.12696","article-title":"Idarucizumab for reversal of dabigatran prior to acute surgery: a schematic approach based on a case report","volume":"120","author":"Rosenberg","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jemermed.2019.09.038_bib27","first-page":"635","article-title":"Idarucizumab: a quick and effective antidote administered prior to coronary artery bypass surgery and mitral valve annuloplasty in a patient treated with dabigatran","volume":"127","author":"Sa\u0142acki","year":"2017","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jemermed.2019.09.038_bib28","first-page":"1393057","article-title":"Reversal of dabigatran using idarucizumab in a septic patient with impaired kidney function in real-life practice","volume":"2016","author":"Sauter","year":"2016","journal-title":"Case Rep Emerg Med"},{"key":"10.1016\/j.jemermed.2019.09.038_bib29","first-page":"6458636","article-title":"First reported case of hemopericardium related to dabigatran use reversed by new antidote idarucizumab","volume":"2017","author":"Song","year":"2017","journal-title":"Case Rep Cardiol"},{"key":"10.1016\/j.jemermed.2019.09.038_bib30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/bja\/aew244","article-title":"Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus","volume":"117","author":"Thorborg","year":"2016","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jemermed.2019.09.038_bib31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/15563650.2016.1187737","article-title":"Idarucizumab for dabigatran overdose","volume":"54","author":"Peetermans","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jemermed.2019.09.038_bib32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14371","article-title":"Idarucizumab for dabigatran overdose in a child","volume":"180","author":"Shapiro","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2019.09.038_bib33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000452096","article-title":"Idarucizumab as antidote to intracerebral hemorrhage under treatment with dabigatran","volume":"8","author":"Held","year":"2016","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.jemermed.2019.09.038_bib34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/1747493017701944","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - a national case collection","volume":"12","author":"Kermer","year":"2017","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jemermed.2019.09.038_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12959-017-0147-z","article-title":"Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report","volume":"15","author":"Tralh\u00e3o","year":"2017","journal-title":"Thromb J"},{"key":"10.1016\/j.jemermed.2019.09.038_bib36","doi-asserted-by":"crossref","first-page":"193.e3","DOI":"10.1016\/j.ajem.2016.06.096","article-title":"Persistent life-threatening hemorrhage after administration of idarucizumab","volume":"35","author":"Alhashem","year":"2017","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jemermed.2019.09.038_bib37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11239-017-1555-4","article-title":"Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence","volume":"44","author":"Giustozzi","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jemermed.2019.09.038_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1213\/XAA.0000000000000395","article-title":"Reversal of anticoagulation with dabigatran in an 82-year-old patient with traumatic retroperitoneal arterial bleeding using the new antidote idarucizumab: a case report","volume":"7","author":"Hofer","year":"2016","journal-title":"A A Case Rep"},{"key":"10.1016\/j.jemermed.2019.09.038_bib39","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1002\/phar.1830","article-title":"Management of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysis","volume":"36","author":"Marino","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jemermed.2019.09.038_bib40","doi-asserted-by":"crossref","first-page":"e0170495","DOI":"10.1371\/journal.pone.0170495","article-title":"Impact of early in-hospital medication review by clinical pharmacists on health services utilization","volume":"12","author":"Hohl","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jemermed.2019.09.038_bib41","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.wneu.2017.10.043","article-title":"Safe burr hole surgery for chronic subdural hematoma using dabigatran with idarucizumab","volume":"109","author":"Arai","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jemermed.2019.09.038_bib42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1941874415569069","article-title":"Dabigatran-associated intracranial hemorrhage: literature review and institutional experience","volume":"5","author":"King","year":"2015","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.jemermed.2019.09.038_bib43","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/jth.12308","article-title":"Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels","volume":"11","author":"Hawes","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2019.09.038_bib44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cll.2014.06.008","article-title":"Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays","volume":"34","author":"van Ryn","year":"2014","journal-title":"Clin Lab Med"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467919308212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467919308212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:44:13Z","timestamp":1760028253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467919308212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0736467919308212"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2019.09.038","relation":{},"ISSN":["0736-4679"],"issn-type":[{"type":"print","value":"0736-4679"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idarucizumab for Reversal of Dabigatran in Early\/Emergency Surgeries: A Case Series","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2019.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}